

Medication for comorbid diseases in end-of-life care in Dutch palliative care facilities

Published: 10-01-2013

Last updated: 26-04-2024

to focus on the patient objectives about medication use for comorbid diseases at the end of life.

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Other condition
Study type	Observational non invasive

Summary

ID

NL-OMON37091

Source

ToetsingOnline

Brief title

medication for comorbid diseases in end-of-life care

Condition

- Other condition

Synonym

terminal care

Health condition

terminale patienten in hospices met diverse beelden

Research involving

Human

Sponsors and support

Primary sponsor: stichting Groenhuysen

Source(s) of monetary or material Support: stichting Groenhuysen;Roosendaal.

Intervention

Keyword: comorbidities, end-of-life care, medication

Outcome measures

Primary outcome

interview material

Secondary outcome

nvt

Study description

Background summary

use of medication for comorbid diseases in terminal care.

Study objective

to focus on the patient objectives about medication use for comorbid diseases at the end of life.

Study design

open interviews, 60 minutes,

Study burden and risks

no risks and no direct benefits for the patient him/herself

Contacts

Public

stichting Groenhuysen

Kalsdonksestraat 89
Roosendaal 4702 ZB
NL

Scientific

stichting Groenhuysen

Kalsdonksestraat 89
Roosendaal 4702 ZB
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

admitted to an hospice or palliative care unit in a nursing home

Exclusion criteria

not able to undergo an interview

Study design

Design

Study type: Observational non invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Health services research

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	01-05-2013
Enrollment:	15
Type:	Actual

Ethics review

Approved WMO	
Date:	10-01-2013
Application type:	First submission
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	16-01-2014
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL41648.091.12